Reaction
Urine Protein/Creatinine Ratio Increased reporting signals
As of the last recalculation, Urine Protein/Creatinine Ratio Increased appears in 879 FAERS reports alongside 21 co-occurring drug terms. The strongest observed disproportionality signal is VOCLOSPORIN (PRR 804.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Voclosporin | 221 | 804.6 | 825.7 |
| Mycophenolic Acid | 50 | 39.2 | 39.2 |
| Entecavir | 12 | 24.7 | 24.7 |
| Mycophenilic Acid | 21 | 24.6 | 24.6 |
| Inclisiran | 8 | 23.8 | 23.9 |
| Tafamidis | 11 | 22.4 | 22.4 |
| Mycophenolate Mofetil | 109 | 21.6 | 21.6 |
| Mycophenolate Mofetil Hydrochloride | 109 | 21.5 | 21.5 |
| Sirolimus | 12 | 21.4 | 21.4 |
| Metolazone | 10 | 21.3 | 21.3 |
| Candesartan | 31 | 21.3 | 21.3 |
| Dapagliflozin | 26 | 20.1 | 20.2 |
| Calcitriol Capsules 0.25 Mcg | 16 | 19.2 | 19.2 |
| Calcitriol Capsules 0.5 Mcg | 16 | 19.2 | 19.2 |
| Calcitriol | 16 | 19.0 | 19.0 |
| Torsemide | 25 | 18.4 | 18.4 |
| Atovaquone | 6 | 17.8 | 17.8 |
| Belimumab | 21 | 16.1 | 16.1 |
| Empagliflozin | 41 | 15.1 | 15.1 |
| Tolvaptan | 8 | 13.1 | 13.2 |
| Obinutuzumab | 6 | 8.7 | 8.7 |